Novartis Expects Clear Demand For Zaditor Following OTC Switch Approval
This article was originally published in The Tan Sheet
Executive Summary
Novartis plans to differentiate its antihistamine eye-drop product Zaditor in the OTC market by positioning the drug as a treatment for the cause, not the symptoms, of itchy eyes